Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma

BACKGROUND: Neuroblastoma (NB) patients with MYCN amplification or overexpression respond poorly to current therapies and exhibit extremely poor clinical outcomes. PI3K-mTOR signaling-driven deregulation of protein synthesis is very common in NB and various other cancers that promote MYCN stabilizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kling, Matthew J., Griggs, Connor N., McIntyre, Erin M., Alexander, Gracey, Ray, Sutapa, Challagundla, Kishore B., Joshi, Shantaram S., Coulter, Don W., Chaturvedi, Nagendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474810/
https://www.ncbi.nlm.nih.gov/pubmed/34565342
http://dx.doi.org/10.1186/s12885-021-08782-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474810/
https://www.ncbi.nlm.nih.gov/pubmed/34565342
http://dx.doi.org/10.1186/s12885-021-08782-9

Ejemplares similares